Vagifem

Atrophic Vaginitis, Low Testosterone, Hypogonadism + 27 more
Treatment
5 FDA approvals
20 Active Studies for Vagifem

What is Vagifem

EstradiolThe Generic name of this drug
Treatment SummaryEstradiol is a hormone naturally produced in females. It is used in hormone therapy to treat conditions related to low estrogen levels, such as hot flashes and vulvovaginal atrophy. It is available in many forms, including tablets, injections, vaginal rings, patches, sprays, gels, and creams. To increase its effectiveness when taken orally or through injection, estradiol is often combined with a pro-drug ester. Ethinyl estradiol is a synthetic form of estradiol that is more bioavailable and resistant to metabolism, making it the most common form used in combination oral contraceptive pills (
Estradermis the brand name
image of different drug pills on a surface
Vagifem Overview & Background
Brand Name
Generic Name
First FDA Approval
How many FDA approvals?
Estraderm
Estradiol
1986
373

Approved as Treatment by the FDA

Estradiol, also known as Estraderm, is approved by the FDA for 5 uses like Hormonal Contraception and Breast Cancer .
Hormonal Contraception
Used to treat Hormonal Contraception therapy in combination with Levonorgestrel
Breast Cancer
Birth Control
Used to treat Contraception in combination with Levonorgestrel
Palliative Treatment
Breast Cancer

Effectiveness

How Vagifem Affects PatientsEstradiol is used to help relieve hot flashes, vaginal dryness, and pain during sex. It also helps increase bone density and can improve the levels of certain proteins in the liver. It can make blood clot more easily, which can increase the risk for heart disease, blood clots in veins, and stroke. Estradiol can also cause an increase in sodium retention and blood pressure.
How Vagifem works in the bodyEstrogen is a hormone found in many parts of the body, like the breast, skin, and brain. In women of reproductive age, the majority of estrogen is made by the ovaries. After menopause, the main source of estrogen is the adrenal glands, which produce androstenedione and then turn it into estrone in other tissues. Estrogen works by binding to two types of receptors, ERα and ERβ, and GPER which helps it take effect quickly. When the receptor binds to estrogen, it travels to the nucleus of the cell and triggers gene transcription. This creates proteins which cause the effects of estrogen

When to interrupt dosage

The measure of Vagifem is founded upon the identified ailment, including Premature Menopause, Pharmaceutical Preparations and Postmenopause. The measure of dosage fluctuates as per the approach of delivery delineated in the table beneath.
Condition
Dosage
Administration
Hormone Replacement Therapy
0.00052 mg/mg, , 0.005 mg/hour, 0.5 mg, 1.0 mg, 0.00025 mg/mg, 0.0005 mg/mg, 0.001 mg/mg, 2.0 mg, 0.0025 mg/hour, 0.0075 mg/hour, 0.01 mg/hour, 0.00375 mg/hour, 0.006 mg/hour, 1.53 mg, 0.0006 mg/mg, 10.0 mg/mL, 40.0 mg/mL, 20.0 mg/mL, 0.0014 mg/hour, 5.0 mg/mL, 0.097 mg/[USP'U], 0.146 mg/[USP'U], 0.194 mg/[USP'U], 4.4 mg, 0.01 mg/[USP'U], 0.01 mg, 10.0 mg, 12.5 mg, 15.0 mg, 18.0 mg, 20.0 mg, 22.0 mg, 25.0 mg, 6.0 mg, 5.0 mg, 0.06 %, 4.0 mg, 8.0 mg, 0.1 %, 3.28 mg, 4.33 mg, 8.66 mg, 6.56 mg, 0.025 mg, 0.00075 mg/mg, 0.51 mg, 0.62 mg, 0.0001 mg/mg, 0.0045 mg/hour, 0.0052 mg/mg, 1.5 mg, 1.8 mg, 2.5 mg/mL, 0.45 mg, 0.9 mg, 0.05 mg, 0.004 mg, 0.0025 mg/mg, 2.17 mg, 6.57 mg, 4.84 mg, 4.95 mg, 14.0 mg, 0.005 mg/mg, 0.0075 mg/mg, 50.0 mg, 0.00125 mg/mg, 0.00005 mg/mg
Topical, Gel, metered, , Gel, metered - Topical, Patch, extended release, Patch, extended release - Transdermal, Transdermal, Tablet, Oral, Tablet - Oral, Tablet, film coated, Tablet, film coated - Oral, Gel, Gel - Topical, Patch - Transdermal, Patch, Ring - Vaginal, Vaginal, Ring, Spray, Spray - Transdermal, Gel - Transdermal, Injection - Intramuscular, Intramuscular, Spray, metered - Transdermal, Tablet, film coated - Vaginal, Spray, metered, Film, extended release - Transdermal, Film, extended release, Pellet, Pellet - Oral, Tablet - Vaginal, Gel, metered - Transdermal, Oral; Transdermal, Insert - Vaginal, Insert, Cream - Vaginal, Cream, Injection, solution - Intramuscular, Lotion - Topical, Emulsion, Emulsion - Topical, Capsule, Capsule - Oral, Pellet, implantable, Pellet, implantable - Subcutaneous, Capsule; Spray, metered - Oral; Transdermal, Cream - Transdermal, Capsule; Spray, metered
Hot Flashes
0.00052 mg/mg, , 0.005 mg/hour, 0.5 mg, 1.0 mg, 0.00025 mg/mg, 0.0005 mg/mg, 0.001 mg/mg, 2.0 mg, 0.0025 mg/hour, 0.0075 mg/hour, 0.01 mg/hour, 0.00375 mg/hour, 0.006 mg/hour, 1.53 mg, 0.0006 mg/mg, 10.0 mg/mL, 40.0 mg/mL, 20.0 mg/mL, 0.0014 mg/hour, 5.0 mg/mL, 0.097 mg/[USP'U], 0.146 mg/[USP'U], 0.194 mg/[USP'U], 4.4 mg, 0.01 mg/[USP'U], 0.01 mg, 10.0 mg, 12.5 mg, 15.0 mg, 18.0 mg, 20.0 mg, 22.0 mg, 25.0 mg, 6.0 mg, 5.0 mg, 0.06 %, 4.0 mg, 8.0 mg, 0.1 %, 3.28 mg, 4.33 mg, 8.66 mg, 6.56 mg, 0.025 mg, 0.00075 mg/mg, 0.51 mg, 0.62 mg, 0.0001 mg/mg, 0.0045 mg/hour, 0.0052 mg/mg, 1.5 mg, 1.8 mg, 2.5 mg/mL, 0.45 mg, 0.9 mg, 0.05 mg, 0.004 mg, 0.0025 mg/mg, 2.17 mg, 6.57 mg, 4.84 mg, 4.95 mg, 14.0 mg, 0.005 mg/mg, 0.0075 mg/mg, 50.0 mg, 0.00125 mg/mg, 0.00005 mg/mg
Topical, Gel, metered, , Gel, metered - Topical, Patch, extended release, Patch, extended release - Transdermal, Transdermal, Tablet, Oral, Tablet - Oral, Tablet, film coated, Tablet, film coated - Oral, Gel, Gel - Topical, Patch - Transdermal, Patch, Ring - Vaginal, Vaginal, Ring, Spray, Spray - Transdermal, Gel - Transdermal, Injection - Intramuscular, Intramuscular, Spray, metered - Transdermal, Tablet, film coated - Vaginal, Spray, metered, Film, extended release - Transdermal, Film, extended release, Pellet, Pellet - Oral, Tablet - Vaginal, Gel, metered - Transdermal, Oral; Transdermal, Insert - Vaginal, Insert, Cream - Vaginal, Cream, Injection, solution - Intramuscular, Lotion - Topical, Emulsion, Emulsion - Topical, Capsule, Capsule - Oral, Pellet, implantable, Pellet, implantable - Subcutaneous, Capsule; Spray, metered - Oral; Transdermal, Cream - Transdermal, Capsule; Spray, metered
Postmenopause
0.00052 mg/mg, , 0.005 mg/hour, 0.5 mg, 1.0 mg, 0.00025 mg/mg, 0.0005 mg/mg, 0.001 mg/mg, 2.0 mg, 0.0025 mg/hour, 0.0075 mg/hour, 0.01 mg/hour, 0.00375 mg/hour, 0.006 mg/hour, 1.53 mg, 0.0006 mg/mg, 10.0 mg/mL, 40.0 mg/mL, 20.0 mg/mL, 0.0014 mg/hour, 5.0 mg/mL, 0.097 mg/[USP'U], 0.146 mg/[USP'U], 0.194 mg/[USP'U], 4.4 mg, 0.01 mg/[USP'U], 0.01 mg, 10.0 mg, 12.5 mg, 15.0 mg, 18.0 mg, 20.0 mg, 22.0 mg, 25.0 mg, 6.0 mg, 5.0 mg, 0.06 %, 4.0 mg, 8.0 mg, 0.1 %, 3.28 mg, 4.33 mg, 8.66 mg, 6.56 mg, 0.025 mg, 0.00075 mg/mg, 0.51 mg, 0.62 mg, 0.0001 mg/mg, 0.0045 mg/hour, 0.0052 mg/mg, 1.5 mg, 1.8 mg, 2.5 mg/mL, 0.45 mg, 0.9 mg, 0.05 mg, 0.004 mg, 0.0025 mg/mg, 2.17 mg, 6.57 mg, 4.84 mg, 4.95 mg, 14.0 mg, 0.005 mg/mg, 0.0075 mg/mg, 50.0 mg, 0.00125 mg/mg, 0.00005 mg/mg
Topical, Gel, metered, , Gel, metered - Topical, Patch, extended release, Patch, extended release - Transdermal, Transdermal, Tablet, Oral, Tablet - Oral, Tablet, film coated, Tablet, film coated - Oral, Gel, Gel - Topical, Patch - Transdermal, Patch, Ring - Vaginal, Vaginal, Ring, Spray, Spray - Transdermal, Gel - Transdermal, Injection - Intramuscular, Intramuscular, Spray, metered - Transdermal, Tablet, film coated - Vaginal, Spray, metered, Film, extended release - Transdermal, Film, extended release, Pellet, Pellet - Oral, Tablet - Vaginal, Gel, metered - Transdermal, Oral; Transdermal, Insert - Vaginal, Insert, Cream - Vaginal, Cream, Injection, solution - Intramuscular, Lotion - Topical, Emulsion, Emulsion - Topical, Capsule, Capsule - Oral, Pellet, implantable, Pellet, implantable - Subcutaneous, Capsule; Spray, metered - Oral; Transdermal, Cream - Transdermal, Capsule; Spray, metered
Balanitis Xerotica Obliterans
0.00052 mg/mg, , 0.005 mg/hour, 0.5 mg, 1.0 mg, 0.00025 mg/mg, 0.0005 mg/mg, 0.001 mg/mg, 2.0 mg, 0.0025 mg/hour, 0.0075 mg/hour, 0.01 mg/hour, 0.00375 mg/hour, 0.006 mg/hour, 1.53 mg, 0.0006 mg/mg, 10.0 mg/mL, 40.0 mg/mL, 20.0 mg/mL, 0.0014 mg/hour, 5.0 mg/mL, 0.097 mg/[USP'U], 0.146 mg/[USP'U], 0.194 mg/[USP'U], 4.4 mg, 0.01 mg/[USP'U], 0.01 mg, 10.0 mg, 12.5 mg, 15.0 mg, 18.0 mg, 20.0 mg, 22.0 mg, 25.0 mg, 6.0 mg, 5.0 mg, 0.06 %, 4.0 mg, 8.0 mg, 0.1 %, 3.28 mg, 4.33 mg, 8.66 mg, 6.56 mg, 0.025 mg, 0.00075 mg/mg, 0.51 mg, 0.62 mg, 0.0001 mg/mg, 0.0045 mg/hour, 0.0052 mg/mg, 1.5 mg, 1.8 mg, 2.5 mg/mL, 0.45 mg, 0.9 mg, 0.05 mg, 0.004 mg, 0.0025 mg/mg, 2.17 mg, 6.57 mg, 4.84 mg, 4.95 mg, 14.0 mg, 0.005 mg/mg, 0.0075 mg/mg, 50.0 mg, 0.00125 mg/mg, 0.00005 mg/mg
Topical, Gel, metered, , Gel, metered - Topical, Patch, extended release, Patch, extended release - Transdermal, Transdermal, Tablet, Oral, Tablet - Oral, Tablet, film coated, Tablet, film coated - Oral, Gel, Gel - Topical, Patch - Transdermal, Patch, Ring - Vaginal, Vaginal, Ring, Spray, Spray - Transdermal, Gel - Transdermal, Injection - Intramuscular, Intramuscular, Spray, metered - Transdermal, Tablet, film coated - Vaginal, Spray, metered, Film, extended release - Transdermal, Film, extended release, Pellet, Pellet - Oral, Tablet - Vaginal, Gel, metered - Transdermal, Oral; Transdermal, Insert - Vaginal, Insert, Cream - Vaginal, Cream, Injection, solution - Intramuscular, Lotion - Topical, Emulsion, Emulsion - Topical, Capsule, Capsule - Oral, Pellet, implantable, Pellet, implantable - Subcutaneous, Capsule; Spray, metered - Oral; Transdermal, Cream - Transdermal, Capsule; Spray, metered
Breast Cancer
0.00052 mg/mg, , 0.005 mg/hour, 0.5 mg, 1.0 mg, 0.00025 mg/mg, 0.0005 mg/mg, 0.001 mg/mg, 2.0 mg, 0.0025 mg/hour, 0.0075 mg/hour, 0.01 mg/hour, 0.00375 mg/hour, 0.006 mg/hour, 1.53 mg, 0.0006 mg/mg, 10.0 mg/mL, 40.0 mg/mL, 20.0 mg/mL, 0.0014 mg/hour, 5.0 mg/mL, 0.097 mg/[USP'U], 0.146 mg/[USP'U], 0.194 mg/[USP'U], 4.4 mg, 0.01 mg/[USP'U], 0.01 mg, 10.0 mg, 12.5 mg, 15.0 mg, 18.0 mg, 20.0 mg, 22.0 mg, 25.0 mg, 6.0 mg, 5.0 mg, 0.06 %, 4.0 mg, 8.0 mg, 0.1 %, 3.28 mg, 4.33 mg, 8.66 mg, 6.56 mg, 0.025 mg, 0.00075 mg/mg, 0.51 mg, 0.62 mg, 0.0001 mg/mg, 0.0045 mg/hour, 0.0052 mg/mg, 1.5 mg, 1.8 mg, 2.5 mg/mL, 0.45 mg, 0.9 mg, 0.05 mg, 0.004 mg, 0.0025 mg/mg, 2.17 mg, 6.57 mg, 4.84 mg, 4.95 mg, 14.0 mg, 0.005 mg/mg, 0.0075 mg/mg, 50.0 mg, 0.00125 mg/mg, 0.00005 mg/mg
Topical, Gel, metered, , Gel, metered - Topical, Patch, extended release, Patch, extended release - Transdermal, Transdermal, Tablet, Oral, Tablet - Oral, Tablet, film coated, Tablet, film coated - Oral, Gel, Gel - Topical, Patch - Transdermal, Patch, Ring - Vaginal, Vaginal, Ring, Spray, Spray - Transdermal, Gel - Transdermal, Injection - Intramuscular, Intramuscular, Spray, metered - Transdermal, Tablet, film coated - Vaginal, Spray, metered, Film, extended release - Transdermal, Film, extended release, Pellet, Pellet - Oral, Tablet - Vaginal, Gel, metered - Transdermal, Oral; Transdermal, Insert - Vaginal, Insert, Cream - Vaginal, Cream, Injection, solution - Intramuscular, Lotion - Topical, Emulsion, Emulsion - Topical, Capsule, Capsule - Oral, Pellet, implantable, Pellet, implantable - Subcutaneous, Capsule; Spray, metered - Oral; Transdermal, Cream - Transdermal, Capsule; Spray, metered
Vasomotor System
0.00052 mg/mg, , 0.005 mg/hour, 0.5 mg, 1.0 mg, 0.00025 mg/mg, 0.0005 mg/mg, 0.001 mg/mg, 2.0 mg, 0.0025 mg/hour, 0.0075 mg/hour, 0.01 mg/hour, 0.00375 mg/hour, 0.006 mg/hour, 1.53 mg, 0.0006 mg/mg, 10.0 mg/mL, 40.0 mg/mL, 20.0 mg/mL, 0.0014 mg/hour, 5.0 mg/mL, 0.097 mg/[USP'U], 0.146 mg/[USP'U], 0.194 mg/[USP'U], 4.4 mg, 0.01 mg/[USP'U], 0.01 mg, 10.0 mg, 12.5 mg, 15.0 mg, 18.0 mg, 20.0 mg, 22.0 mg, 25.0 mg, 6.0 mg, 5.0 mg, 0.06 %, 4.0 mg, 8.0 mg, 0.1 %, 3.28 mg, 4.33 mg, 8.66 mg, 6.56 mg, 0.025 mg, 0.00075 mg/mg, 0.51 mg, 0.62 mg, 0.0001 mg/mg, 0.0045 mg/hour, 0.0052 mg/mg, 1.5 mg, 1.8 mg, 2.5 mg/mL, 0.45 mg, 0.9 mg, 0.05 mg, 0.004 mg, 0.0025 mg/mg, 2.17 mg, 6.57 mg, 4.84 mg, 4.95 mg, 14.0 mg, 0.005 mg/mg, 0.0075 mg/mg, 50.0 mg, 0.00125 mg/mg, 0.00005 mg/mg
Topical, Gel, metered, , Gel, metered - Topical, Patch, extended release, Patch, extended release - Transdermal, Transdermal, Tablet, Oral, Tablet - Oral, Tablet, film coated, Tablet, film coated - Oral, Gel, Gel - Topical, Patch - Transdermal, Patch, Ring - Vaginal, Vaginal, Ring, Spray, Spray - Transdermal, Gel - Transdermal, Injection - Intramuscular, Intramuscular, Spray, metered - Transdermal, Tablet, film coated - Vaginal, Spray, metered, Film, extended release - Transdermal, Film, extended release, Pellet, Pellet - Oral, Tablet - Vaginal, Gel, metered - Transdermal, Oral; Transdermal, Insert - Vaginal, Insert, Cream - Vaginal, Cream, Injection, solution - Intramuscular, Lotion - Topical, Emulsion, Emulsion - Topical, Capsule, Capsule - Oral, Pellet, implantable, Pellet, implantable - Subcutaneous, Capsule; Spray, metered - Oral; Transdermal, Cream - Transdermal, Capsule; Spray, metered
estradiol
0.00052 mg/mg, , 0.005 mg/hour, 0.5 mg, 1.0 mg, 0.00025 mg/mg, 0.0005 mg/mg, 0.001 mg/mg, 2.0 mg, 0.0025 mg/hour, 0.0075 mg/hour, 0.01 mg/hour, 0.00375 mg/hour, 0.006 mg/hour, 1.53 mg, 0.0006 mg/mg, 10.0 mg/mL, 40.0 mg/mL, 20.0 mg/mL, 0.0014 mg/hour, 5.0 mg/mL, 0.097 mg/[USP'U], 0.146 mg/[USP'U], 0.194 mg/[USP'U], 4.4 mg, 0.01 mg/[USP'U], 0.01 mg, 10.0 mg, 12.5 mg, 15.0 mg, 18.0 mg, 20.0 mg, 22.0 mg, 25.0 mg, 6.0 mg, 5.0 mg, 0.06 %, 4.0 mg, 8.0 mg, 0.1 %, 3.28 mg, 4.33 mg, 8.66 mg, 6.56 mg, 0.025 mg, 0.00075 mg/mg, 0.51 mg, 0.62 mg, 0.0001 mg/mg, 0.0045 mg/hour, 0.0052 mg/mg, 1.5 mg, 1.8 mg, 2.5 mg/mL, 0.45 mg, 0.9 mg, 0.05 mg, 0.004 mg, 0.0025 mg/mg, 2.17 mg, 6.57 mg, 4.84 mg, 4.95 mg, 14.0 mg, 0.005 mg/mg, 0.0075 mg/mg, 50.0 mg, 0.00125 mg/mg, 0.00005 mg/mg
Topical, Gel, metered, , Gel, metered - Topical, Patch, extended release, Patch, extended release - Transdermal, Transdermal, Tablet, Oral, Tablet - Oral, Tablet, film coated, Tablet, film coated - Oral, Gel, Gel - Topical, Patch - Transdermal, Patch, Ring - Vaginal, Vaginal, Ring, Spray, Spray - Transdermal, Gel - Transdermal, Injection - Intramuscular, Intramuscular, Spray, metered - Transdermal, Tablet, film coated - Vaginal, Spray, metered, Film, extended release - Transdermal, Film, extended release, Pellet, Pellet - Oral, Tablet - Vaginal, Gel, metered - Transdermal, Oral; Transdermal, Insert - Vaginal, Insert, Cream - Vaginal, Cream, Injection, solution - Intramuscular, Lotion - Topical, Emulsion, Emulsion - Topical, Capsule, Capsule - Oral, Pellet, implantable, Pellet, implantable - Subcutaneous, Capsule; Spray, metered - Oral; Transdermal, Cream - Transdermal, Capsule; Spray, metered
Breast
0.00052 mg/mg, , 0.005 mg/hour, 0.5 mg, 1.0 mg, 0.00025 mg/mg, 0.0005 mg/mg, 0.001 mg/mg, 2.0 mg, 0.0025 mg/hour, 0.0075 mg/hour, 0.01 mg/hour, 0.00375 mg/hour, 0.006 mg/hour, 1.53 mg, 0.0006 mg/mg, 10.0 mg/mL, 40.0 mg/mL, 20.0 mg/mL, 0.0014 mg/hour, 5.0 mg/mL, 0.097 mg/[USP'U], 0.146 mg/[USP'U], 0.194 mg/[USP'U], 4.4 mg, 0.01 mg/[USP'U], 0.01 mg, 10.0 mg, 12.5 mg, 15.0 mg, 18.0 mg, 20.0 mg, 22.0 mg, 25.0 mg, 6.0 mg, 5.0 mg, 0.06 %, 4.0 mg, 8.0 mg, 0.1 %, 3.28 mg, 4.33 mg, 8.66 mg, 6.56 mg, 0.025 mg, 0.00075 mg/mg, 0.51 mg, 0.62 mg, 0.0001 mg/mg, 0.0045 mg/hour, 0.0052 mg/mg, 1.5 mg, 1.8 mg, 2.5 mg/mL, 0.45 mg, 0.9 mg, 0.05 mg, 0.004 mg, 0.0025 mg/mg, 2.17 mg, 6.57 mg, 4.84 mg, 4.95 mg, 14.0 mg, 0.005 mg/mg, 0.0075 mg/mg, 50.0 mg, 0.00125 mg/mg, 0.00005 mg/mg
Topical, Gel, metered, , Gel, metered - Topical, Patch, extended release, Patch, extended release - Transdermal, Transdermal, Tablet, Oral, Tablet - Oral, Tablet, film coated, Tablet, film coated - Oral, Gel, Gel - Topical, Patch - Transdermal, Patch, Ring - Vaginal, Vaginal, Ring, Spray, Spray - Transdermal, Gel - Transdermal, Injection - Intramuscular, Intramuscular, Spray, metered - Transdermal, Tablet, film coated - Vaginal, Spray, metered, Film, extended release - Transdermal, Film, extended release, Pellet, Pellet - Oral, Tablet - Vaginal, Gel, metered - Transdermal, Oral; Transdermal, Insert - Vaginal, Insert, Cream - Vaginal, Cream, Injection, solution - Intramuscular, Lotion - Topical, Emulsion, Emulsion - Topical, Capsule, Capsule - Oral, Pellet, implantable, Pellet, implantable - Subcutaneous, Capsule; Spray, metered - Oral; Transdermal, Cream - Transdermal, Capsule; Spray, metered
Hot flashes
0.00052 mg/mg, , 0.005 mg/hour, 0.5 mg, 1.0 mg, 0.00025 mg/mg, 0.0005 mg/mg, 0.001 mg/mg, 2.0 mg, 0.0025 mg/hour, 0.0075 mg/hour, 0.01 mg/hour, 0.00375 mg/hour, 0.006 mg/hour, 1.53 mg, 0.0006 mg/mg, 10.0 mg/mL, 40.0 mg/mL, 20.0 mg/mL, 0.0014 mg/hour, 5.0 mg/mL, 0.097 mg/[USP'U], 0.146 mg/[USP'U], 0.194 mg/[USP'U], 4.4 mg, 0.01 mg/[USP'U], 0.01 mg, 10.0 mg, 12.5 mg, 15.0 mg, 18.0 mg, 20.0 mg, 22.0 mg, 25.0 mg, 6.0 mg, 5.0 mg, 0.06 %, 4.0 mg, 8.0 mg, 0.1 %, 3.28 mg, 4.33 mg, 8.66 mg, 6.56 mg, 0.025 mg, 0.00075 mg/mg, 0.51 mg, 0.62 mg, 0.0001 mg/mg, 0.0045 mg/hour, 0.0052 mg/mg, 1.5 mg, 1.8 mg, 2.5 mg/mL, 0.45 mg, 0.9 mg, 0.05 mg, 0.004 mg, 0.0025 mg/mg, 2.17 mg, 6.57 mg, 4.84 mg, 4.95 mg, 14.0 mg, 0.005 mg/mg, 0.0075 mg/mg, 50.0 mg, 0.00125 mg/mg, 0.00005 mg/mg
Topical, Gel, metered, , Gel, metered - Topical, Patch, extended release, Patch, extended release - Transdermal, Transdermal, Tablet, Oral, Tablet - Oral, Tablet, film coated, Tablet, film coated - Oral, Gel, Gel - Topical, Patch - Transdermal, Patch, Ring - Vaginal, Vaginal, Ring, Spray, Spray - Transdermal, Gel - Transdermal, Injection - Intramuscular, Intramuscular, Spray, metered - Transdermal, Tablet, film coated - Vaginal, Spray, metered, Film, extended release - Transdermal, Film, extended release, Pellet, Pellet - Oral, Tablet - Vaginal, Gel, metered - Transdermal, Oral; Transdermal, Insert - Vaginal, Insert, Cream - Vaginal, Cream, Injection, solution - Intramuscular, Lotion - Topical, Emulsion, Emulsion - Topical, Capsule, Capsule - Oral, Pellet, implantable, Pellet, implantable - Subcutaneous, Capsule; Spray, metered - Oral; Transdermal, Cream - Transdermal, Capsule; Spray, metered
Amenorrhea
0.00052 mg/mg, , 0.005 mg/hour, 0.5 mg, 1.0 mg, 0.00025 mg/mg, 0.0005 mg/mg, 0.001 mg/mg, 2.0 mg, 0.0025 mg/hour, 0.0075 mg/hour, 0.01 mg/hour, 0.00375 mg/hour, 0.006 mg/hour, 1.53 mg, 0.0006 mg/mg, 10.0 mg/mL, 40.0 mg/mL, 20.0 mg/mL, 0.0014 mg/hour, 5.0 mg/mL, 0.097 mg/[USP'U], 0.146 mg/[USP'U], 0.194 mg/[USP'U], 4.4 mg, 0.01 mg/[USP'U], 0.01 mg, 10.0 mg, 12.5 mg, 15.0 mg, 18.0 mg, 20.0 mg, 22.0 mg, 25.0 mg, 6.0 mg, 5.0 mg, 0.06 %, 4.0 mg, 8.0 mg, 0.1 %, 3.28 mg, 4.33 mg, 8.66 mg, 6.56 mg, 0.025 mg, 0.00075 mg/mg, 0.51 mg, 0.62 mg, 0.0001 mg/mg, 0.0045 mg/hour, 0.0052 mg/mg, 1.5 mg, 1.8 mg, 2.5 mg/mL, 0.45 mg, 0.9 mg, 0.05 mg, 0.004 mg, 0.0025 mg/mg, 2.17 mg, 6.57 mg, 4.84 mg, 4.95 mg, 14.0 mg, 0.005 mg/mg, 0.0075 mg/mg, 50.0 mg, 0.00125 mg/mg, 0.00005 mg/mg
Topical, Gel, metered, , Gel, metered - Topical, Patch, extended release, Patch, extended release - Transdermal, Transdermal, Tablet, Oral, Tablet - Oral, Tablet, film coated, Tablet, film coated - Oral, Gel, Gel - Topical, Patch - Transdermal, Patch, Ring - Vaginal, Vaginal, Ring, Spray, Spray - Transdermal, Gel - Transdermal, Injection - Intramuscular, Intramuscular, Spray, metered - Transdermal, Tablet, film coated - Vaginal, Spray, metered, Film, extended release - Transdermal, Film, extended release, Pellet, Pellet - Oral, Tablet - Vaginal, Gel, metered - Transdermal, Oral; Transdermal, Insert - Vaginal, Insert, Cream - Vaginal, Cream, Injection, solution - Intramuscular, Lotion - Topical, Emulsion, Emulsion - Topical, Capsule, Capsule - Oral, Pellet, implantable, Pellet, implantable - Subcutaneous, Capsule; Spray, metered - Oral; Transdermal, Cream - Transdermal, Capsule; Spray, metered
Palliative Treatment
0.00052 mg/mg, , 0.005 mg/hour, 0.5 mg, 1.0 mg, 0.00025 mg/mg, 0.0005 mg/mg, 0.001 mg/mg, 2.0 mg, 0.0025 mg/hour, 0.0075 mg/hour, 0.01 mg/hour, 0.00375 mg/hour, 0.006 mg/hour, 1.53 mg, 0.0006 mg/mg, 10.0 mg/mL, 40.0 mg/mL, 20.0 mg/mL, 0.0014 mg/hour, 5.0 mg/mL, 0.097 mg/[USP'U], 0.146 mg/[USP'U], 0.194 mg/[USP'U], 4.4 mg, 0.01 mg/[USP'U], 0.01 mg, 10.0 mg, 12.5 mg, 15.0 mg, 18.0 mg, 20.0 mg, 22.0 mg, 25.0 mg, 6.0 mg, 5.0 mg, 0.06 %, 4.0 mg, 8.0 mg, 0.1 %, 3.28 mg, 4.33 mg, 8.66 mg, 6.56 mg, 0.025 mg, 0.00075 mg/mg, 0.51 mg, 0.62 mg, 0.0001 mg/mg, 0.0045 mg/hour, 0.0052 mg/mg, 1.5 mg, 1.8 mg, 2.5 mg/mL, 0.45 mg, 0.9 mg, 0.05 mg, 0.004 mg, 0.0025 mg/mg, 2.17 mg, 6.57 mg, 4.84 mg, 4.95 mg, 14.0 mg, 0.005 mg/mg, 0.0075 mg/mg, 50.0 mg, 0.00125 mg/mg, 0.00005 mg/mg
Topical, Gel, metered, , Gel, metered - Topical, Patch, extended release, Patch, extended release - Transdermal, Transdermal, Tablet, Oral, Tablet - Oral, Tablet, film coated, Tablet, film coated - Oral, Gel, Gel - Topical, Patch - Transdermal, Patch, Ring - Vaginal, Vaginal, Ring, Spray, Spray - Transdermal, Gel - Transdermal, Injection - Intramuscular, Intramuscular, Spray, metered - Transdermal, Tablet, film coated - Vaginal, Spray, metered, Film, extended release - Transdermal, Film, extended release, Pellet, Pellet - Oral, Tablet - Vaginal, Gel, metered - Transdermal, Oral; Transdermal, Insert - Vaginal, Insert, Cream - Vaginal, Cream, Injection, solution - Intramuscular, Lotion - Topical, Emulsion, Emulsion - Topical, Capsule, Capsule - Oral, Pellet, implantable, Pellet, implantable - Subcutaneous, Capsule; Spray, metered - Oral; Transdermal, Cream - Transdermal, Capsule; Spray, metered
Pharmaceutical Preparations
0.00052 mg/mg, , 0.005 mg/hour, 0.5 mg, 1.0 mg, 0.00025 mg/mg, 0.0005 mg/mg, 0.001 mg/mg, 2.0 mg, 0.0025 mg/hour, 0.0075 mg/hour, 0.01 mg/hour, 0.00375 mg/hour, 0.006 mg/hour, 1.53 mg, 0.0006 mg/mg, 10.0 mg/mL, 40.0 mg/mL, 20.0 mg/mL, 0.0014 mg/hour, 5.0 mg/mL, 0.097 mg/[USP'U], 0.146 mg/[USP'U], 0.194 mg/[USP'U], 4.4 mg, 0.01 mg/[USP'U], 0.01 mg, 10.0 mg, 12.5 mg, 15.0 mg, 18.0 mg, 20.0 mg, 22.0 mg, 25.0 mg, 6.0 mg, 5.0 mg, 0.06 %, 4.0 mg, 8.0 mg, 0.1 %, 3.28 mg, 4.33 mg, 8.66 mg, 6.56 mg, 0.025 mg, 0.00075 mg/mg, 0.51 mg, 0.62 mg, 0.0001 mg/mg, 0.0045 mg/hour, 0.0052 mg/mg, 1.5 mg, 1.8 mg, 2.5 mg/mL, 0.45 mg, 0.9 mg, 0.05 mg, 0.004 mg, 0.0025 mg/mg, 2.17 mg, 6.57 mg, 4.84 mg, 4.95 mg, 14.0 mg, 0.005 mg/mg, 0.0075 mg/mg, 50.0 mg, 0.00125 mg/mg, 0.00005 mg/mg
Topical, Gel, metered, , Gel, metered - Topical, Patch, extended release, Patch, extended release - Transdermal, Transdermal, Tablet, Oral, Tablet - Oral, Tablet, film coated, Tablet, film coated - Oral, Gel, Gel - Topical, Patch - Transdermal, Patch, Ring - Vaginal, Vaginal, Ring, Spray, Spray - Transdermal, Gel - Transdermal, Injection - Intramuscular, Intramuscular, Spray, metered - Transdermal, Tablet, film coated - Vaginal, Spray, metered, Film, extended release - Transdermal, Film, extended release, Pellet, Pellet - Oral, Tablet - Vaginal, Gel, metered - Transdermal, Oral; Transdermal, Insert - Vaginal, Insert, Cream - Vaginal, Cream, Injection, solution - Intramuscular, Lotion - Topical, Emulsion, Emulsion - Topical, Capsule, Capsule - Oral, Pellet, implantable, Pellet, implantable - Subcutaneous, Capsule; Spray, metered - Oral; Transdermal, Cream - Transdermal, Capsule; Spray, metered
female castration
0.00052 mg/mg, , 0.005 mg/hour, 0.5 mg, 1.0 mg, 0.00025 mg/mg, 0.0005 mg/mg, 0.001 mg/mg, 2.0 mg, 0.0025 mg/hour, 0.0075 mg/hour, 0.01 mg/hour, 0.00375 mg/hour, 0.006 mg/hour, 1.53 mg, 0.0006 mg/mg, 10.0 mg/mL, 40.0 mg/mL, 20.0 mg/mL, 0.0014 mg/hour, 5.0 mg/mL, 0.097 mg/[USP'U], 0.146 mg/[USP'U], 0.194 mg/[USP'U], 4.4 mg, 0.01 mg/[USP'U], 0.01 mg, 10.0 mg, 12.5 mg, 15.0 mg, 18.0 mg, 20.0 mg, 22.0 mg, 25.0 mg, 6.0 mg, 5.0 mg, 0.06 %, 4.0 mg, 8.0 mg, 0.1 %, 3.28 mg, 4.33 mg, 8.66 mg, 6.56 mg, 0.025 mg, 0.00075 mg/mg, 0.51 mg, 0.62 mg, 0.0001 mg/mg, 0.0045 mg/hour, 0.0052 mg/mg, 1.5 mg, 1.8 mg, 2.5 mg/mL, 0.45 mg, 0.9 mg, 0.05 mg, 0.004 mg, 0.0025 mg/mg, 2.17 mg, 6.57 mg, 4.84 mg, 4.95 mg, 14.0 mg, 0.005 mg/mg, 0.0075 mg/mg, 50.0 mg, 0.00125 mg/mg, 0.00005 mg/mg
Topical, Gel, metered, , Gel, metered - Topical, Patch, extended release, Patch, extended release - Transdermal, Transdermal, Tablet, Oral, Tablet - Oral, Tablet, film coated, Tablet, film coated - Oral, Gel, Gel - Topical, Patch - Transdermal, Patch, Ring - Vaginal, Vaginal, Ring, Spray, Spray - Transdermal, Gel - Transdermal, Injection - Intramuscular, Intramuscular, Spray, metered - Transdermal, Tablet, film coated - Vaginal, Spray, metered, Film, extended release - Transdermal, Film, extended release, Pellet, Pellet - Oral, Tablet - Vaginal, Gel, metered - Transdermal, Oral; Transdermal, Insert - Vaginal, Insert, Cream - Vaginal, Cream, Injection, solution - Intramuscular, Lotion - Topical, Emulsion, Emulsion - Topical, Capsule, Capsule - Oral, Pellet, implantable, Pellet, implantable - Subcutaneous, Capsule; Spray, metered - Oral; Transdermal, Cream - Transdermal, Capsule; Spray, metered
Premature Menopause
0.00052 mg/mg, , 0.005 mg/hour, 0.5 mg, 1.0 mg, 0.00025 mg/mg, 0.0005 mg/mg, 0.001 mg/mg, 2.0 mg, 0.0025 mg/hour, 0.0075 mg/hour, 0.01 mg/hour, 0.00375 mg/hour, 0.006 mg/hour, 1.53 mg, 0.0006 mg/mg, 10.0 mg/mL, 40.0 mg/mL, 20.0 mg/mL, 0.0014 mg/hour, 5.0 mg/mL, 0.097 mg/[USP'U], 0.146 mg/[USP'U], 0.194 mg/[USP'U], 4.4 mg, 0.01 mg/[USP'U], 0.01 mg, 10.0 mg, 12.5 mg, 15.0 mg, 18.0 mg, 20.0 mg, 22.0 mg, 25.0 mg, 6.0 mg, 5.0 mg, 0.06 %, 4.0 mg, 8.0 mg, 0.1 %, 3.28 mg, 4.33 mg, 8.66 mg, 6.56 mg, 0.025 mg, 0.00075 mg/mg, 0.51 mg, 0.62 mg, 0.0001 mg/mg, 0.0045 mg/hour, 0.0052 mg/mg, 1.5 mg, 1.8 mg, 2.5 mg/mL, 0.45 mg, 0.9 mg, 0.05 mg, 0.004 mg, 0.0025 mg/mg, 2.17 mg, 6.57 mg, 4.84 mg, 4.95 mg, 14.0 mg, 0.005 mg/mg, 0.0075 mg/mg, 50.0 mg, 0.00125 mg/mg, 0.00005 mg/mg
Topical, Gel, metered, , Gel, metered - Topical, Patch, extended release, Patch, extended release - Transdermal, Transdermal, Tablet, Oral, Tablet - Oral, Tablet, film coated, Tablet, film coated - Oral, Gel, Gel - Topical, Patch - Transdermal, Patch, Ring - Vaginal, Vaginal, Ring, Spray, Spray - Transdermal, Gel - Transdermal, Injection - Intramuscular, Intramuscular, Spray, metered - Transdermal, Tablet, film coated - Vaginal, Spray, metered, Film, extended release - Transdermal, Film, extended release, Pellet, Pellet - Oral, Tablet - Vaginal, Gel, metered - Transdermal, Oral; Transdermal, Insert - Vaginal, Insert, Cream - Vaginal, Cream, Injection, solution - Intramuscular, Lotion - Topical, Emulsion, Emulsion - Topical, Capsule, Capsule - Oral, Pellet, implantable, Pellet, implantable - Subcutaneous, Capsule; Spray, metered - Oral; Transdermal, Cream - Transdermal, Capsule; Spray, metered
Atrophic
0.00052 mg/mg, , 0.005 mg/hour, 0.5 mg, 1.0 mg, 0.00025 mg/mg, 0.0005 mg/mg, 0.001 mg/mg, 2.0 mg, 0.0025 mg/hour, 0.0075 mg/hour, 0.01 mg/hour, 0.00375 mg/hour, 0.006 mg/hour, 1.53 mg, 0.0006 mg/mg, 10.0 mg/mL, 40.0 mg/mL, 20.0 mg/mL, 0.0014 mg/hour, 5.0 mg/mL, 0.097 mg/[USP'U], 0.146 mg/[USP'U], 0.194 mg/[USP'U], 4.4 mg, 0.01 mg/[USP'U], 0.01 mg, 10.0 mg, 12.5 mg, 15.0 mg, 18.0 mg, 20.0 mg, 22.0 mg, 25.0 mg, 6.0 mg, 5.0 mg, 0.06 %, 4.0 mg, 8.0 mg, 0.1 %, 3.28 mg, 4.33 mg, 8.66 mg, 6.56 mg, 0.025 mg, 0.00075 mg/mg, 0.51 mg, 0.62 mg, 0.0001 mg/mg, 0.0045 mg/hour, 0.0052 mg/mg, 1.5 mg, 1.8 mg, 2.5 mg/mL, 0.45 mg, 0.9 mg, 0.05 mg, 0.004 mg, 0.0025 mg/mg, 2.17 mg, 6.57 mg, 4.84 mg, 4.95 mg, 14.0 mg, 0.005 mg/mg, 0.0075 mg/mg, 50.0 mg, 0.00125 mg/mg, 0.00005 mg/mg
Topical, Gel, metered, , Gel, metered - Topical, Patch, extended release, Patch, extended release - Transdermal, Transdermal, Tablet, Oral, Tablet - Oral, Tablet, film coated, Tablet, film coated - Oral, Gel, Gel - Topical, Patch - Transdermal, Patch, Ring - Vaginal, Vaginal, Ring, Spray, Spray - Transdermal, Gel - Transdermal, Injection - Intramuscular, Intramuscular, Spray, metered - Transdermal, Tablet, film coated - Vaginal, Spray, metered, Film, extended release - Transdermal, Film, extended release, Pellet, Pellet - Oral, Tablet - Vaginal, Gel, metered - Transdermal, Oral; Transdermal, Insert - Vaginal, Insert, Cream - Vaginal, Cream, Injection, solution - Intramuscular, Lotion - Topical, Emulsion, Emulsion - Topical, Capsule, Capsule - Oral, Pellet, implantable, Pellet, implantable - Subcutaneous, Capsule; Spray, metered - Oral; Transdermal, Cream - Transdermal, Capsule; Spray, metered
Prostate Cancer
0.00052 mg/mg, , 0.005 mg/hour, 0.5 mg, 1.0 mg, 0.00025 mg/mg, 0.0005 mg/mg, 0.001 mg/mg, 2.0 mg, 0.0025 mg/hour, 0.0075 mg/hour, 0.01 mg/hour, 0.00375 mg/hour, 0.006 mg/hour, 1.53 mg, 0.0006 mg/mg, 10.0 mg/mL, 40.0 mg/mL, 20.0 mg/mL, 0.0014 mg/hour, 5.0 mg/mL, 0.097 mg/[USP'U], 0.146 mg/[USP'U], 0.194 mg/[USP'U], 4.4 mg, 0.01 mg/[USP'U], 0.01 mg, 10.0 mg, 12.5 mg, 15.0 mg, 18.0 mg, 20.0 mg, 22.0 mg, 25.0 mg, 6.0 mg, 5.0 mg, 0.06 %, 4.0 mg, 8.0 mg, 0.1 %, 3.28 mg, 4.33 mg, 8.66 mg, 6.56 mg, 0.025 mg, 0.00075 mg/mg, 0.51 mg, 0.62 mg, 0.0001 mg/mg, 0.0045 mg/hour, 0.0052 mg/mg, 1.5 mg, 1.8 mg, 2.5 mg/mL, 0.45 mg, 0.9 mg, 0.05 mg, 0.004 mg, 0.0025 mg/mg, 2.17 mg, 6.57 mg, 4.84 mg, 4.95 mg, 14.0 mg, 0.005 mg/mg, 0.0075 mg/mg, 50.0 mg, 0.00125 mg/mg, 0.00005 mg/mg
Topical, Gel, metered, , Gel, metered - Topical, Patch, extended release, Patch, extended release - Transdermal, Transdermal, Tablet, Oral, Tablet - Oral, Tablet, film coated, Tablet, film coated - Oral, Gel, Gel - Topical, Patch - Transdermal, Patch, Ring - Vaginal, Vaginal, Ring, Spray, Spray - Transdermal, Gel - Transdermal, Injection - Intramuscular, Intramuscular, Spray, metered - Transdermal, Tablet, film coated - Vaginal, Spray, metered, Film, extended release - Transdermal, Film, extended release, Pellet, Pellet - Oral, Tablet - Vaginal, Gel, metered - Transdermal, Oral; Transdermal, Insert - Vaginal, Insert, Cream - Vaginal, Cream, Injection, solution - Intramuscular, Lotion - Topical, Emulsion, Emulsion - Topical, Capsule, Capsule - Oral, Pellet, implantable, Pellet, implantable - Subcutaneous, Capsule; Spray, metered - Oral; Transdermal, Cream - Transdermal, Capsule; Spray, metered
Therapeutic procedure
0.00052 mg/mg, , 0.005 mg/hour, 0.5 mg, 1.0 mg, 0.00025 mg/mg, 0.0005 mg/mg, 0.001 mg/mg, 2.0 mg, 0.0025 mg/hour, 0.0075 mg/hour, 0.01 mg/hour, 0.00375 mg/hour, 0.006 mg/hour, 1.53 mg, 0.0006 mg/mg, 10.0 mg/mL, 40.0 mg/mL, 20.0 mg/mL, 0.0014 mg/hour, 5.0 mg/mL, 0.097 mg/[USP'U], 0.146 mg/[USP'U], 0.194 mg/[USP'U], 4.4 mg, 0.01 mg/[USP'U], 0.01 mg, 10.0 mg, 12.5 mg, 15.0 mg, 18.0 mg, 20.0 mg, 22.0 mg, 25.0 mg, 6.0 mg, 5.0 mg, 0.06 %, 4.0 mg, 8.0 mg, 0.1 %, 3.28 mg, 4.33 mg, 8.66 mg, 6.56 mg, 0.025 mg, 0.00075 mg/mg, 0.51 mg, 0.62 mg, 0.0001 mg/mg, 0.0045 mg/hour, 0.0052 mg/mg, 1.5 mg, 1.8 mg, 2.5 mg/mL, 0.45 mg, 0.9 mg, 0.05 mg, 0.004 mg, 0.0025 mg/mg, 2.17 mg, 6.57 mg, 4.84 mg, 4.95 mg, 14.0 mg, 0.005 mg/mg, 0.0075 mg/mg, 50.0 mg, 0.00125 mg/mg, 0.00005 mg/mg
Topical, Gel, metered, , Gel, metered - Topical, Patch, extended release, Patch, extended release - Transdermal, Transdermal, Tablet, Oral, Tablet - Oral, Tablet, film coated, Tablet, film coated - Oral, Gel, Gel - Topical, Patch - Transdermal, Patch, Ring - Vaginal, Vaginal, Ring, Spray, Spray - Transdermal, Gel - Transdermal, Injection - Intramuscular, Intramuscular, Spray, metered - Transdermal, Tablet, film coated - Vaginal, Spray, metered, Film, extended release - Transdermal, Film, extended release, Pellet, Pellet - Oral, Tablet - Vaginal, Gel, metered - Transdermal, Oral; Transdermal, Insert - Vaginal, Insert, Cream - Vaginal, Cream, Injection, solution - Intramuscular, Lotion - Topical, Emulsion, Emulsion - Topical, Capsule, Capsule - Oral, Pellet, implantable, Pellet, implantable - Subcutaneous, Capsule; Spray, metered - Oral; Transdermal, Cream - Transdermal, Capsule; Spray, metered
Hypogonadism
0.00052 mg/mg, , 0.005 mg/hour, 0.5 mg, 1.0 mg, 0.00025 mg/mg, 0.0005 mg/mg, 0.001 mg/mg, 2.0 mg, 0.0025 mg/hour, 0.0075 mg/hour, 0.01 mg/hour, 0.00375 mg/hour, 0.006 mg/hour, 1.53 mg, 0.0006 mg/mg, 10.0 mg/mL, 40.0 mg/mL, 20.0 mg/mL, 0.0014 mg/hour, 5.0 mg/mL, 0.097 mg/[USP'U], 0.146 mg/[USP'U], 0.194 mg/[USP'U], 4.4 mg, 0.01 mg/[USP'U], 0.01 mg, 10.0 mg, 12.5 mg, 15.0 mg, 18.0 mg, 20.0 mg, 22.0 mg, 25.0 mg, 6.0 mg, 5.0 mg, 0.06 %, 4.0 mg, 8.0 mg, 0.1 %, 3.28 mg, 4.33 mg, 8.66 mg, 6.56 mg, 0.025 mg, 0.00075 mg/mg, 0.51 mg, 0.62 mg, 0.0001 mg/mg, 0.0045 mg/hour, 0.0052 mg/mg, 1.5 mg, 1.8 mg, 2.5 mg/mL, 0.45 mg, 0.9 mg, 0.05 mg, 0.004 mg, 0.0025 mg/mg, 2.17 mg, 6.57 mg, 4.84 mg, 4.95 mg, 14.0 mg, 0.005 mg/mg, 0.0075 mg/mg, 50.0 mg, 0.00125 mg/mg, 0.00005 mg/mg
Topical, Gel, metered, , Gel, metered - Topical, Patch, extended release, Patch, extended release - Transdermal, Transdermal, Tablet, Oral, Tablet - Oral, Tablet, film coated, Tablet, film coated - Oral, Gel, Gel - Topical, Patch - Transdermal, Patch, Ring - Vaginal, Vaginal, Ring, Spray, Spray - Transdermal, Gel - Transdermal, Injection - Intramuscular, Intramuscular, Spray, metered - Transdermal, Tablet, film coated - Vaginal, Spray, metered, Film, extended release - Transdermal, Film, extended release, Pellet, Pellet - Oral, Tablet - Vaginal, Gel, metered - Transdermal, Oral; Transdermal, Insert - Vaginal, Insert, Cream - Vaginal, Cream, Injection, solution - Intramuscular, Lotion - Topical, Emulsion, Emulsion - Topical, Capsule, Capsule - Oral, Pellet, implantable, Pellet, implantable - Subcutaneous, Capsule; Spray, metered - Oral; Transdermal, Cream - Transdermal, Capsule; Spray, metered
Osteoporosis
0.00052 mg/mg, , 0.005 mg/hour, 0.5 mg, 1.0 mg, 0.00025 mg/mg, 0.0005 mg/mg, 0.001 mg/mg, 2.0 mg, 0.0025 mg/hour, 0.0075 mg/hour, 0.01 mg/hour, 0.00375 mg/hour, 0.006 mg/hour, 1.53 mg, 0.0006 mg/mg, 10.0 mg/mL, 40.0 mg/mL, 20.0 mg/mL, 0.0014 mg/hour, 5.0 mg/mL, 0.097 mg/[USP'U], 0.146 mg/[USP'U], 0.194 mg/[USP'U], 4.4 mg, 0.01 mg/[USP'U], 0.01 mg, 10.0 mg, 12.5 mg, 15.0 mg, 18.0 mg, 20.0 mg, 22.0 mg, 25.0 mg, 6.0 mg, 5.0 mg, 0.06 %, 4.0 mg, 8.0 mg, 0.1 %, 3.28 mg, 4.33 mg, 8.66 mg, 6.56 mg, 0.025 mg, 0.00075 mg/mg, 0.51 mg, 0.62 mg, 0.0001 mg/mg, 0.0045 mg/hour, 0.0052 mg/mg, 1.5 mg, 1.8 mg, 2.5 mg/mL, 0.45 mg, 0.9 mg, 0.05 mg, 0.004 mg, 0.0025 mg/mg, 2.17 mg, 6.57 mg, 4.84 mg, 4.95 mg, 14.0 mg, 0.005 mg/mg, 0.0075 mg/mg, 50.0 mg, 0.00125 mg/mg, 0.00005 mg/mg
Topical, Gel, metered, , Gel, metered - Topical, Patch, extended release, Patch, extended release - Transdermal, Transdermal, Tablet, Oral, Tablet - Oral, Tablet, film coated, Tablet, film coated - Oral, Gel, Gel - Topical, Patch - Transdermal, Patch, Ring - Vaginal, Vaginal, Ring, Spray, Spray - Transdermal, Gel - Transdermal, Injection - Intramuscular, Intramuscular, Spray, metered - Transdermal, Tablet, film coated - Vaginal, Spray, metered, Film, extended release - Transdermal, Film, extended release, Pellet, Pellet - Oral, Tablet - Vaginal, Gel, metered - Transdermal, Oral; Transdermal, Insert - Vaginal, Insert, Cream - Vaginal, Cream, Injection, solution - Intramuscular, Lotion - Topical, Emulsion, Emulsion - Topical, Capsule, Capsule - Oral, Pellet, implantable, Pellet, implantable - Subcutaneous, Capsule; Spray, metered - Oral; Transdermal, Cream - Transdermal, Capsule; Spray, metered
hypoestrogenism
0.00052 mg/mg, , 0.005 mg/hour, 0.5 mg, 1.0 mg, 0.00025 mg/mg, 0.0005 mg/mg, 0.001 mg/mg, 2.0 mg, 0.0025 mg/hour, 0.0075 mg/hour, 0.01 mg/hour, 0.00375 mg/hour, 0.006 mg/hour, 1.53 mg, 0.0006 mg/mg, 10.0 mg/mL, 40.0 mg/mL, 20.0 mg/mL, 0.0014 mg/hour, 5.0 mg/mL, 0.097 mg/[USP'U], 0.146 mg/[USP'U], 0.194 mg/[USP'U], 4.4 mg, 0.01 mg/[USP'U], 0.01 mg, 10.0 mg, 12.5 mg, 15.0 mg, 18.0 mg, 20.0 mg, 22.0 mg, 25.0 mg, 6.0 mg, 5.0 mg, 0.06 %, 4.0 mg, 8.0 mg, 0.1 %, 3.28 mg, 4.33 mg, 8.66 mg, 6.56 mg, 0.025 mg, 0.00075 mg/mg, 0.51 mg, 0.62 mg, 0.0001 mg/mg, 0.0045 mg/hour, 0.0052 mg/mg, 1.5 mg, 1.8 mg, 2.5 mg/mL, 0.45 mg, 0.9 mg, 0.05 mg, 0.004 mg, 0.0025 mg/mg, 2.17 mg, 6.57 mg, 4.84 mg, 4.95 mg, 14.0 mg, 0.005 mg/mg, 0.0075 mg/mg, 50.0 mg, 0.00125 mg/mg, 0.00005 mg/mg
Topical, Gel, metered, , Gel, metered - Topical, Patch, extended release, Patch, extended release - Transdermal, Transdermal, Tablet, Oral, Tablet - Oral, Tablet, film coated, Tablet, film coated - Oral, Gel, Gel - Topical, Patch - Transdermal, Patch, Ring - Vaginal, Vaginal, Ring, Spray, Spray - Transdermal, Gel - Transdermal, Injection - Intramuscular, Intramuscular, Spray, metered - Transdermal, Tablet, film coated - Vaginal, Spray, metered, Film, extended release - Transdermal, Film, extended release, Pellet, Pellet - Oral, Tablet - Vaginal, Gel, metered - Transdermal, Oral; Transdermal, Insert - Vaginal, Insert, Cream - Vaginal, Cream, Injection, solution - Intramuscular, Lotion - Topical, Emulsion, Emulsion - Topical, Capsule, Capsule - Oral, Pellet, implantable, Pellet, implantable - Subcutaneous, Capsule; Spray, metered - Oral; Transdermal, Cream - Transdermal, Capsule; Spray, metered

Warnings

Vagifem has eighteen known contraindications and should be avoided for those experiencing the conditions given in the following table.Vagifem Contraindications
Condition
Risk Level
Notes
Breast
Do Not Combine
Angioedema
Do Not Combine
Venous Thrombosis
Do Not Combine
undiagnosed abnormal genital bleeding
Do Not Combine
estrogen-dependent neoplasia
Do Not Combine
Liver Dysfunction
Do Not Combine
Breast
Do Not Combine
suspected pregnancy
Do Not Combine
Breast Cancer
Do Not Combine
Pulmonary Embolism
Do Not Combine
Angioedema
Do Not Combine
Deep Vein Thrombosis
Do Not Combine
Thromboembolism
Do Not Combine
Neoplasms, Hormone-Dependent
Do Not Combine
Pulmonary Embolism
Do Not Combine
Thromboembolism
Do Not Combine
Thrombophilia
Do Not Combine
Severe Hypersensitivity Reactions
Do Not Combine
Estradiol may interact with Pulse Frequency
There are 20 known major drug interactions with Vagifem.
Common Vagifem Drug Interactions
Drug Name
Risk Level
Description
Aminophylline
Major
The metabolism of Aminophylline can be decreased when combined with Estradiol.
Anagrelide
Major
The metabolism of Anagrelide can be decreased when combined with Estradiol.
Anastrozole
Major
The therapeutic efficacy of Anastrozole can be decreased when used in combination with Estradiol.
Astemizole
Major
The metabolism of Astemizole can be decreased when combined with Estradiol.
Axitinib
Major
The metabolism of Axitinib can be decreased when combined with Estradiol.
Vagifem Toxicity & Overdose RiskStudies have found that taking estradiol for 90 days in rats had no adverse effects at doses of 0.003 mg/kg/day. The lowest toxic dose for ethinyl estradiol is 21 mg/kg/21D for women. An overdose of estradiol may cause nausea, vomiting, abdominal pain, breast tenderness, blood clots, and vaginal bleeding. If you suspect an overdose, it is recommended to stop taking the drug and get supportive care.
image of a doctor in a lab doing drug, clinical research

Vagifem Novel Uses: Which Conditions Have a Clinical Trial Featuring Vagifem?

867 ongoing studies are assessing the potential of Vagifem to alleviate Osteoporosis, absent menses for the preceding 6 months, and Urogenital Atrophy.
Condition
Clinical Trials
Trial Phases
Hysterectomy
3 Actively Recruiting
Phase 3, Not Applicable
Breast Cancer
21 Actively Recruiting
Phase 2, Phase 1, Not Applicable
estradiol
0 Actively Recruiting
Birth Control
22 Actively Recruiting
Not Applicable, Phase 3, Phase 4, Early Phase 1, Phase 2
Postmenopause
5 Actively Recruiting
Phase 2, Not Applicable
Metastatic Breast Cancer
1 Actively Recruiting
Phase 1, Phase 2
Osteoporosis, Postmenopausal
0 Actively Recruiting
Therapeutic procedure
0 Actively Recruiting
moderate to severe symptoms
0 Actively Recruiting
Balanitis Xerotica Obliterans
0 Actively Recruiting
Amenorrhea
1 Actively Recruiting
Phase 2
Osteoporosis
27 Actively Recruiting
Not Applicable, Phase 4, Phase 1, Phase 3, Phase 2
Prostate Cancer
68 Actively Recruiting
Not Applicable, Phase 3, Phase 2, Phase 1, Early Phase 1
Breast
0 Actively Recruiting
Urogenital atrophy
0 Actively Recruiting
Low Testosterone
6 Actively Recruiting
Phase 4, Phase 2, Phase 1
Vasomotor System
0 Actively Recruiting
Atrophic Vaginitis
1 Actively Recruiting
Not Applicable
Hot flashes
19 Actively Recruiting
Not Applicable, Phase 4, Phase 2, Early Phase 1, Phase 3
Hormone Replacement Therapy
0 Actively Recruiting

Vagifem Reviews: What are patients saying about Vagifem?

4.3Patient Review
5/16/2022
Vagifem for Postmenopausal Urethral Atrophy
As someone who has gone through menopause, I've found this treatment to be very effective for my bladder problems and dry vagina. I haven't experienced any negative side effects, though there is the occasional thrush infection which may be caused by the applicator. Overall, this has worked well for me.
3.7Patient Review
5/11/2022
Vagifem for Wasting of Tissues of the Vulva
I've gained nine pounds, my breasts are larger and tender, my hair is falling out more quickly, I feel breathless and get mild headaches. While the moisturizing effect seems to have decreased, I do feel more comfortable deep inside and no longer feel like I have a UTI brewing all the time.
3Patient Review
8/9/2022
Vagifem for Postmenopausal Urethral Atrophy
I initially had no issues with this medication, but after about a month I started to experience really unpleasant side effects like bloating, leg cramps, and hair loss. I'm hoping to speak to my doctor soon about discontinuing use.
3Patient Review
11/6/2022
Vagifem for Vaginal Inflammation due to Loss of Hormone Stimulation
I did not do my research on this medication before taking it, and I regret that now. I can't say for certain whether or not Vagifem is causing my problems, but it's certainly possible. I've been experiencing extreme bloating and pelvic pain which has made daily life very difficult. Additionally, I'm constantly feeling the need to urinate. The one side effect that concerns me most after reading these reviews is hair loss. I have already lost 50% of my hair, and the texture has changed for the worse. As of now, I will be stopping use of this medication."
2.7Patient Review
4/29/2022
Vagifem for Vaginal Inflammation due to Loss of Hormone Stimulation
I used this for five months to try and alleviate vaginal atrophy, but it only made the burning and stinging sensations worse. It also seemed to make my slight vaginal prolapse much worse. On top of all that, I got the worst thrush ever. So, on balance, I think I would have been better off without it.
2.7Patient Review
5/5/2022
Vagifem for Postmenopausal Urethral Atrophy
I developed a really bad itch and discharge after using this for about eight days. It was like a yeast infection, so I stopped taking it immediately.
2.3Patient Review
4/20/2022
Vagifem for Wasting of Tissues of the Vulva
The new Vagirux applicator is too shallow and the tablet falls out constantly.
1Patient Review
3/14/2022
Vagifem for Marked Inflammation of Urethra, the Canal that leads From the Bladder
I've only been using this medication for four days, and I woke up this morning in excruciating pain. I'm continuing to take it as directed because I need a smear test, but the pain is unbearable. I don't know how I'm supposed to make it through 10 more days of this.
1Patient Review
10/11/2022
Vagifem for Vaginal Inflammation due to Loss of Hormone Stimulation
The burning was unbearable and I felt like I had to constantly go to the bathroom. The pressure in my bladder was really intense.
1Patient Review
2/25/2022
Vagifem for Vaginal Inflammation due to Loss of Hormone Stimulation
I have Ehlers-Danlos Syndrome and this medication made me very sick.
image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about vagifem

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What are the risks of taking Vagifem?

"Vagifem® users most often reported experiencing headache, breast pain, irregular vaginal bleeding or spotting, stomach/abdominal cramps, bloating, nausea and vomiting, hair loss, fluid retention, and vaginal yeast infection."

Answered by AI

How quickly will Vagifem work?

"A study found that the drug Vagifem 10 mcg helped to reduce symptoms associated with vaginal atrophy in most women after 12 weeks of treatment, though some women reported seeing improvements as early as 8 weeks into treatment."

Answered by AI

What does Vagifem do for a woman?

"This medication is used to help reduce vaginal symptoms of menopause in women. These symptoms are caused by the body making less estrogen and can include vaginal dryness, burning, and itching."

Answered by AI

How long should you stay on Vagifem?

"It is currently recommended to continue using local estrogen therapy for as long as it is needed for symptom control. A study that looked back at data from over 13,000 women showed that, in the real world, local estrogen therapy is typically used for around 12 months."

Answered by AI

Clinical Trials for Vagifem

Image of Altasciences in Mount Royal, Canada.

Elinzanetant for Hot Flashes

18 - 65
Female
Mount Royal, Canada
The aim of this study is to examine the relative bioavailability of elinzanetant when administered in new oral formulations (treatment B and C) after both single and multiple oral doses, compared to its administration in soft gel capsule form (treatment A). Study details include: An ambulatory screening visit within 4 weeks prior to first treatment. Participants will be admitted to the ward on Day -1 of each period. On Day 1, either treatment B or treatment C will be administered fasted in the evening, followed by blood sampling for a 24-hour pharmacokinetic (PK) profile. On Day 2, the multiple dosing starts 3 hours after a standardized dinner in the evening. After the last dosing on Day 7, a complete PK profile for 24 hours will be collected. If there are no medical objections, participants will be discharged from the study ward on Day 9 in the morning for a washout-out period of at least 10 days (240 hours after last dosing, after period 1 and 2) or, in period 3, after the follow-up examination. The total duration of the study will be approximately 10 to 12 weeks for each participant.
Phase 1
Recruiting
AltasciencesBayer
Image of Washington University School of Medicine in St Louis, United States.

Radium-223 for Prostate Cancer

18+
Male
St Louis, MO
Internal radiotherapies (radiolabeled molecules that are systemically administered and localize to sites of disease) provide cancer-ablating doses to diseased cells while sparing adjacent normal tissues. \[223Ra\]RaCl2 (Xofigo) is the first FDA-approved alpha-particle emitting radiopharmaceutical therapy (αRPT), providing a survival benefit for men with bone metastatic castration-resistant prostate cancer. Systemically administered radiotherapies distribute throughout the patient, accumulating to unknown levels at sites of disease and in radiosensitive vital organs. The whole-body distribution means that absorbed doses in the patient extend far beyond a pre-defined treatment field. There is a lack of information about αRPT distribution and localization, and this confounds treatment monitoring, complicates dose and schedule personalization, and impedes drug development. Single-photon emission computed tomography (SPECT) imaging offers a mechanism to quantify uptake; however, αRPT administered activities are significantly lower than those used with diagnostic procedures, which presents a challenge for quantitation with conventional methods. Preliminary research shows that low-count quantitative SPECT (LC-QSPECT) imaging demonstrates reliable quantitation of regional uptake for αRPTs. The purpose of this study is to demonstrate the feasibility, tolerability and performance of LC-QSPECT imaging.
Waitlist Available
Has No Placebo
Washington University School of MedicineAbhinav K Jha, Ph.D.
Image of City of Hope Medical Center in Duarte, United States.

Oral Cryotherapy for Prostate Cancer

18+
Male
Duarte, CA
This clinical trial studies whether cooling the mouth with popsicles (oral cryotherapy) decreases taste changes in prostate cancer patients receiving taxane chemotherapy. Patients receiving chemotherapy can experience a variety of side effects. Changes in the taste of food is a frequent complaint of patients receiving chemotherapy and is underreported as patients may think that it is unavoidable and not manageable. Taxane-based chemotherapy is thought to be associated with the most taste changes of any chemotherapy. Taste buds contain a specific type of cell, called gustatory cells, that are located on the surface of the tongue, the soft palate (back, muscular part of the roof of the mouth), and the upper part of the esophagus. These cells consist of five basic tastes: salty, sweet, sour, bitter, and umami (or savory). Oral cryotherapy involves cooling the mouth with ice chips, popsicles, or other cold drinks for several minutes before, during, and after chemotherapy causing the tiny blood vessels in the protective linings inside the mouth to narrow. It is thought that this narrowing will reduce blood flow to the cooled areas, thereby decreasing the amount of chemotherapy that is delivered to the fragile protective linings inside the mouth that causes the taste changes. This may be an effective way to decrease taste changes in prostate cancer patients receiving taxane chemotherapy.
Recruiting
Has No Placebo
City of Hope Medical CenterJeannine M Brant
Have you considered Vagifem clinical trials? We made a collection of clinical trials featuring Vagifem, we think they might fit your search criteria.Go to Trials
Image of City of Hope Medical Center in Duarte, United States.

Metabolic Interventions for Prostate Cancer

30 - 79
Male
Duarte, CA
This phase II trial compares the effect of time-restricted eating (TRE) and glucagon-like peptide-1 (GLP1) receptor agonists (RA), semaglutide and tirzepatide, to an American Heart Association (AHA) heart healthy diet (HHD) intervention on heart and blood vessel health (cardiovascular system) and how the body processes food for energy (metabolic system) in prostate cancer patients undergoing androgen deprivation therapy (ADT). Prostate cancer patients who are receiving hormonal therapy (ADT) are at an increased risk of cardiovascular disease. This is thought to be due to treatment-related metabolic changes which may result in increased weight, body fat, insulin resistance and an increased risk of heart attack, stroke or other heart and blood vessel problems. TRE (also known as intermittent fasting) is an eating plan that alternates between fasting and non-fasting periods. This approach limits calorie intake to a specific window of time each day. GLP1-RAs, semaglutide and tirzepatide are in a class of medications called incretin mimetics. They work by helping the pancreas to release the right amount of insulin when blood sugar levels are high. Insulin helps move sugar from the blood into other body tissues where it is used for energy. They also slow the movement of food through the stomach and may decrease appetite and cause weight loss. The AHA HHD guidelines may be an effective method to help people learn about following a heart healthy eating plan. This may lower their risk of cardiovascular disease. Metabolic interventions, TRE and GLP1-RA, may be more effective than an AHA HHD intervention alone in improving cardiovascular and metabolic health in prostate cancer patients undergoing ADT.
Phase 2
Recruiting
City of Hope Medical CenterRose Li
Image of UCLA / Jonsson Comprehensive Cancer Center in Los Angeles, United States.

Flotufolastat F 18 PET/CT for Prostate Cancer

18 - 90
Male
Los Angeles, CA
This phase II trial evaluates how well flotufolastat F 18 positron emission tomography (PET)/computed tomography (CT) imaging works to detect cancer that remains (residual) or that has come back (recurrent) after the completion of focal therapy for prostate cancer. Flotufolastat F 18 is a radioactive tracer that binds to prostate specific membrane antigen (PSMA), a protein over-expressed on prostate tumor cells. This allows for visualization of PSMA-expressing cells upon imaging. PET is an established imaging technique that utilizes small amounts of radioactivity attached to very minimal amounts of, in the case of this research, flotufolastat F 18. Because prostate cancer takes up flotufolastat F 18, it can be seen with PET. CT utilizes x-rays that track the body from the outside. CT images provide an exact outline of the organs and potential inflammatory tissue where it occurs in the body. The PET/CT scanner combines the PET and the CT scanners into a single device. This device combines the anatomic (body structure) information provided by the CT scan with the metabolic information obtained from the PET scan. Metabolic information means how much of the injected tracer is taken up by inflammatory tissue. Flotufolastat F 18 PET/CT imaging may be an effective and less invasive way to detect residual or recurrent disease in prostate cancer patients, compared to other methods.
Phase 2
Recruiting
UCLA / Jonsson Comprehensive Cancer CenterWayne BrisbaneBlue Earth Diagnostics
Image of UCLA / Jonsson Comprehensive Cancer Center in Los Angeles, United States.

PSMA Imaging for Prostate Cancer

18 - 90
Male
Los Angeles, CA
This early phase I trial evaluates whether a new imaging technique using flotufolastat F 18 (a type of prostate specific membrane antigen \[PSMA\] imaging agent) with positron emission tomography (PET)/computed tomography (CT) can be used to guide targeted prostate biopsies in men with prostate cancer. Flotufolastat F 18 is a radioactive imaging agent that binds to prostate tumor cells that express PSMA. This allows for visualization of PSMA-expressing tumor cells on imaging scans such as PET/CT. PET is an established imaging technique that utilizes small amounts of radioactivity attached to very minimal amounts of tracer, in the case of this research, flotufolastat F 18. Because prostate cancer takes up flotufolastat F 18, it can be seen with PET. CT utilizes X-rays that track the body from the outside. CT images provide an exact outline of organs and potential inflammatory tissue where it occurs in the body. The PET/CT scanner combines the PET and the CT scanners into a single device. A targeted prostate biopsy refers to using advanced imaging for guidance when taking samples (biopsies) of the prostate. This method can fuse (combine) PET/CT images with real-time ultrasound during a prostate biopsy. PSMA PET/CT scans have the potential for guiding prostate biopsies. Using image fusion technology, they can increase detection of prostate cancer by providing anatomical information and guidance during a prostate biopsy. Improved detection of prostate cancer using PSMA PET/CT guidance may better inform men and their clinicians about prostate cancer risk and management. This study attempts to determine how often prostate cancer is found when using PSMA PET/CT scan images during a biopsy versus the conventional magnetic resonance imaging-guidance.
Phase < 1
Recruiting
UCLA / Jonsson Comprehensive Cancer CenterWayne BrisbaneBlue Earth Diagnostics
Have you considered Vagifem clinical trials? We made a collection of clinical trials featuring Vagifem, we think they might fit your search criteria.Go to Trials
Image of Mayo Clinic in Florida in Jacksonville, United States.

Virtual Reality Assistant for Prostate Cancer

Any Age
Male
Jacksonville, FL
This clinical trial tests how well a point of prostate cancer diagnosis (PPCD) virtual reality assistant (ViRA) intervention works in supporting Black men with newly diagnosed prostate cancer. Cancer is the second leading cause of death for African American/Black men, with prostate cancer leading in estimated new cancer cases and second in estimated new cancer deaths. Over 40,000 African American/Black men are diagnosed with prostate cancer annually, with 1 in 6 lifetime probability of developing prostate cancer compared to 1 in 8 probability in White men. The PPCD ViRA provides psycho-oncology support, social determinants of health navigation and emotional support for ethnically diverse African American/Black men newly diagnosed with prostate cancer using artificial intelligence and augmented reality. Using PPCD ViRA may close the prostate cancer care gap for African American/Black men across the cancer continuum and provide emotional, educational, and resource needs of this population when they are visiting a doctor about their prostate health or prostate cancer.
Waitlist Available
Has No Placebo
Mayo Clinic in FloridaFolakemi T. Odedina, PhD
Have you considered Vagifem clinical trials? We made a collection of clinical trials featuring Vagifem, we think they might fit your search criteria.Go to Trials
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security